Guardian Bio is centred on developing a personalised cell therapy based on dendritic cells.
Guardian Bio has raised $500K in total funding. The most recent round was Pre-Seed. The last funding was announced in August 2022.
Guardian Bio's investors include Y Combinator.
Guardian Bio is headquartered in Boston, United States.
Guardian Bio is centred on developing a personalised cell therapy based on dendritic cells.
Guardian Bio is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Guardian Bio — Funding & Investors." VCBacked, August 22, 2022, https://www.vcbacked.co/company/guardian-bio. Accessed August 14, 2026.
VCBacked. (2022). Guardian Bio — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/guardian-bio
{{cite web |title=Guardian Bio — Funding & Investors |url=https://www.vcbacked.co/company/guardian-bio |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated